StockData
FRNMNasdaqServices-Medical LaboratoriesFiscal year ends December 31

Freenome, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 15, 2026
$12.57+0.82 (+6.98%)

Close on Oct 19, 2026

Market cap
–
P/E (TTM)
–
Dividend yield
–

About Freenome

Services-Medical Laboratories, SIC 8071

Perceptive Capital Solutions Corp operates as a blank check company established to effect a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The entity does not manufacture commercial products, offer services, or maintain distinct operating business segments. Because it functions as an acquisition vehicle rather than an operating commercial enterprise, the company does not serve commercial clients or retail consumers. Instead, its core business activity centers on identifying, evaluating, and negotiating a potential initial transaction with private or public operating enterprises, concentrating primarily on companies within the healthcare sector, specifically life sciences and medical technology.

The organization maintains its principal executive offices in New York, New York, and is organized as an exempted company under the laws of the Cayman Islands. As a shell entity without commercial operations, it owns no stores or manufacturing plants. Geographically, its acquisition focus spans prospective corporate targets located in North America and Europe.

Summary of the business section of Freenome's latest annual report, written by StockData.

Company profile

Company

Legal name
Freenome, Inc.
Founded
2024
Headquarters
Brisbane, CA
Address
Genesis Marina, 3300 Marina Blvd 94005
Phone
(212) 284-2300
Employees
19, Dec 31, 2025
Industry
Services-Medical Laboratories
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
WithumSmith+Brown, PC, New York, New York

Stock & identifiers

Ticker
FRNM
Exchange
Nasdaq
IPO date
Jun 12, 2024
Shares outstanding
10M, Jul 15, 2026
Public float
$91.60M, Jun 30, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
SEC CIK
2017526
CUSIP
35661P100
ISIN
US35661P1003
EIN
00-0000000

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Aaron Matthew ElliottChief Executive Officer, Director345,976
Riley Charles EnnisChief Product Officer2,864,366
Cheng-Ho Jimmy LinChief Scientific Officer410,154
Linh H. LeChief Financial Officer64,294
Deepika PakianathanDirector13,918
Randal W. ScottDirector104,204
Oort Douglas M. VanDirector20,867
Ann Catherine CostelloDirector–
Carole NuechterleinDirector–
Capital Healthcare Fund LP RADirector–
Rajeev M. ShahDirector750,000
RA Capital Nexus Fund III, L.P.Director–
Peter KolchinskyDirector–
RA Capital Nexus Fund, L.P.Director1,245,068
Ra Capital Management, L.P.Director–
RA Capital Nexus Fund II, L.P.Director–

Employees

Headcount reported in annual reports

“● our success in retaining or recruiting, or changes required in, our officers, key employees or directors following our initial business combination; … ● our ability to consummate an initial business combination, including the Proposed Freenome Business Combination, due to the uncertainty resulting from geopolitical tensions or conflicts such as the ongoing conflicts between Russia and Ukraine, Israel and Iran, and Israel and Hamas, acts of war or terrorism, economic impacts such as inflation, ”

Corporate history

Events identified from SEC filings